FEATURED
What implications will Trump’s “Big Beautiful Bill” have for Global Life Sciences?
We discuss the potential impact on U.S research institutions, the pharmaceutical, biotech, and medtech industries, and what the shifting landscape might mean for organisations operating in or engaging with the United States, the United Kingdom, and Europe.
